Chemogenics Biopharma

Contribution to design and synthesis of Commercial and Clinical Compounds: Trilaciclib and Lerociclib ChemoGenics BioPharma excels in multiple phases of preclinical drug discovery. Our core strengths are Medicinal Chemistry, process optimization, scale up, animal (rodent) dosing studies, DMPK, bioanalytical studies (tissue and plasma matrices). We have several collaborative medicinal chemistry programs in various target areas. Our internally developed compound has entered human trials as a first in class chemoprotective agent. We have several other compounds entering human clinical trials for other indications. We want to use our expertise to help companies identify molecules that could enter human clinical trials. State of art instrumentation for bioanalytical work: Sciex 4000QTRAP, Sciex 5500 coupled to Agilent HPLC/UPLC